Jane Claire Williams, MD
Gastroenterology · Flowood, MSNPI 1578760534
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $10,400 of the $15,688 with a category attached, or 66.3%. AbbVie accounts for 71.0% of it on its own, with 24 other manufacturers making up the rest. Reporting peaked in 2019 at $12,224 and has fallen 97.4% since, to $317 in 2025.
Across 185 payments — averaging $84.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$11K
- Boston Scientific$2K
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$548
- Takeda Pharmaceuticals U.S.A., Inc.$518
- Bristol Myers Squibb$367
- Ironwood Pharmaceuticals, Inc$188
- plus $1K from 19 others
Across 31 payments — averaging $8244.27 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Boehringer Ingelheim$246K
- Boehringer Ingelheim RCV GmbH & Co KG$10K
What the payments were for
- Speaking & faculty fees$10,40066%
- Travel & lodging$6914%
- Food & beverage$4,53329%
- Education$640%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 29 | $11,141 |
| Boston Scientific | 16 | $1,657 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 34 | $548 |
| Takeda Pharmaceuticals U.S.A., Inc. | 28 | $518 |
| Bristol Myers Squibb | 30 | $367 |
| Ironwood Pharmaceuticals, Inc | 7 | $188 |
| Phathom Pharmaceuticals, Inc. | 8 | $162 |
| Ambu Inc. | 1 | $145 |
| Intercept Pharmaceuticals, Inc. | 9 | $141 |
| Mauna Kea Technologies, Inc. | 1 | $140 |
| Conmed Corporation | 1 | $136 |
| Apollo Endosurgery US Inc | 1 | $119 |
| Sanofi | 4 | $88 |
| W. L. Gore & Associates, Inc. | 1 | $64 |
| Johnson & Johnson | 3 | $55 |
| Ipsen Biopharmaceuticals, Inc | 2 | $35 |
| Nestle Healthcare Nutrition Inc. | 2 | $32 |
| Braintree Laboratories, Inc. | 1 | $31 |
| QOL Medical, LLC | 1 | $25 |
| Aimmune Therapeutics, Inc. | 1 | $21 |
| Pharmacosmos Therapeutics Inc. | 1 | $17 |
| Alnylam Pharmaceuticals Inc. | 1 | $17 |
| Ardelyx, Inc. | 1 | $15 |
| AstraZeneca | 1 | $13 |
| Pfizer | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LINZESS$8,144
- VIBERZI$2,623
- GENERAL - BILIARY DEVICES$691
- SPYGLASS$243
- CONMED BILIARY$136
- OverStitch Endoscopic Suturing System$119
- ORISE$118
- EXALT Model D$107
- EXALT$102
- GENERAL BIOPSY$101
How this compares
$15,688 in reported general payments places this provider in the 85th percentile of 127 gastroenterology providers in Mississippi.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| StelaraUstekinumab | 15 | $412,372 |
| OcalivaObeticholic Acid | 13 | $124,632 |
| LinzessLinaclotide | 54 | $43,498 |
| ClenpiqSod Picosulf/Mag Ox/Citric Ac | 63 | $10,129 |
| Colesevelam Hcl | 62 | $7,629 |
| Omeprazole | 378 | $3,165 |
| PlenvuPeg3350/Sod Sul/Nacl/Kcl/Asb/C | 19 | $2,713 |
| Sucralfate | 48 | $2,133 |
| Peg 3350-ElectrolyteSodium Chloride/Nahco3/Kcl/Peg | 67 | $1,917 |
| Mesalamine ErMesalamine | 15 | $1,848 |
| Budesonide DrBudesonide | 15 | $1,785 |
| Pantoprazole Sodium | 148 | $1,622 |
| Gavilyte-CPeg3350/Sod Sulf,bicarb,cl/Kcl | 98 | $1,533 |
| Famotidine | 93 | $1,072 |
| CholestyramineCholestyramine (With Sugar) | 24 | $1,060 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonStelara | $55 | $412,37215 claims |
| Intercept Pharmaceuticals, Inc.Ocaliva | $141 | $124,63213 claims |
| AbbVieLinzess | $11,141 | $43,49854 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCPlenvu | $548 | $2,71319 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 127 gastroenterology providers in Mississippi.
Other gastroenterology in Flowood
- Reed HoganFlowood$216K
- Vonda ReevesFlowood$39K
- Reed HoganFlowood$35K
- Ronald KotfilaFlowood$10K
- Stewart BoydFlowood$4K
- Wassem JuakiemBiloxi$519K
- John PhillipsTupelo$150K
- Brian BorgJackson$68K
- Pegah Hosseini-CarrollJackson$62K
- Shou Jiang TangJackson$50K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.